MaxCyte, Inc. (MXCT)Healthcare | Medical Devices | Rockville, United States | NasdaqGS
1.38 USD
+0.05
(3.759%)
⇧
(July 13, 2026, 4 p.m.
EDT)
After hours: 1.39 +0.01 (0.725%) ⇧ (July 13, 2026, 6:51 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 5:50 a.m. EDT
The investment case for MaxCyte is currently defined by a stark disconnect between its deteriorating operational reality and speculative hopes for a future turnaround. Fundamentally, the business is under severe stress: revenue contracted by 7.1% last year, and the company is burning cash with negative operating margins of nearly 64%. The price action confirms this distress, as the stock has lost more than half its value over the past three years, with the last two annual periods showing double-digit declines. While the balance sheet remains surprisingly robust with a current ratio of 12, the lack of free cash flow and negative returns on equity suggest the core engine is stalled. The recent news of missing revenue estimates reinforces this bearish trend. On the short end, the statistical forecast leans negative, and despite the lack of put buying, the momentum is clearly downward. The massive call activity seen in the Jan 2027 expiration represents a speculative wager on a successful pivot or acquisition, but it does not alter the fact that the current business is failing to generate value. This is a high-risk situation where the 'value' of the cheap stock price is likely just the market pricing in a continued struggle rather than a hidden gem. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.256954 |
| MSTL | 0.292511 |
| AutoARIMA | 0.295434 |
| AutoETS | 0.295450 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 26% |
| H-stat | 3.28 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 1.84 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 10.416 |
| Revenue per Share | 0.303 |
| Market Cap | 147,827,904 |
| Forward P/E | -5.86 |
| Beta | 1.66 |
| Profit Margins | -121.16% |
| Website | https://www.maxcyte.com |
As of July 11, 2026, 5:50 a.m. EDT: Speculators are overwhelmingly bullish on the longer horizon, with massive open interest concentrated in January 2027 calls at the $2.50 strike, suggesting a bet on a significant recovery. However, this optimism is not reflected in the immediate term; July 2026 options show heavy out-of-the-money call positioning relative to volume, while put activity is virtually non-existent, indicating traders are positioning for volatility rather than a specific directional move in the near week.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.40625 |
| Address1 | 9,713 Key West Avenue |
| Address2 | Suite 400 |
| All Time High | 17.44 |
| All Time Low | 0.643 |
| Ask | 1.71 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 2,301,230 |
| Average Daily Volume3 Month | 1,187,631 |
| Average Volume | 1,187,631 |
| Average Volume10Days | 2,301,230 |
| Beta | 1.663 |
| Bid | 1.05 |
| Bid Size | 2 |
| Board Risk | 6 |
| Book Value | 1.567 |
| City | Rockville |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.38 |
| Current Ratio | 12.038 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 1.48 |
| Day Low | 1.325 |
| Debt To Equity | 10.416 |
| Display Name | MaxCyte |
| Earnings Call Timestamp End | 1,778,617,800 |
| Earnings Call Timestamp Start | 1,778,617,800 |
| Earnings Timestamp | 1,778,616,000 |
| Earnings Timestamp End | 1,786,564,800 |
| Earnings Timestamp Start | 1,786,564,800 |
| Ebitda | -34,161,000 |
| Ebitda Margins | -1.05804 |
| Enterprise To Ebitda | -1.711 |
| Enterprise To Revenue | 1.811 |
| Enterprise Value | 58,460,908 |
| Eps Current Year | -0.27497 |
| Eps Forward | -0.2354 |
| Eps Trailing Twelve Months | -0.36 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.103 |
| Fifty Day Average Change | 0.27699995 |
| Fifty Day Average Change Percent | 0.2511332 |
| Fifty Two Week Change Percent | -40.625 |
| Fifty Two Week High | 2.37 |
| Fifty Two Week High Change | -0.9899999 |
| Fifty Two Week High Change Percent | -0.41772148 |
| Fifty Two Week Low | 0.643 |
| Fifty Two Week Low Change | 0.737 |
| Fifty Two Week Low Change Percent | 1.1461897 |
| Fifty Two Week Range | 0.643 - 2.37 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,627,651,800,000 |
| Float Shares | 97,631,763 |
| Forward Eps | -0.2354 |
| Forward P E | -5.862362 |
| Free Cashflow | -14,128,000 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 91 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.80505997 |
| Gross Profits | 25,993,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01593 |
| Held Percent Institutions | 0.68184996 |
| Implied Shares Outstanding | 107,121,672 |
| Industry | Medical Devices |
| Industry Disp | Medical Devices |
| Industry Key | medical-devices |
| Ipo Expected Date | 2,021-07-30 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. The company has strategic partnership with VectorBuilder focused on co-developing a new gene delivery solution. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland. |
| Long Name | MaxCyte, Inc. |
| Market | us_market |
| Market Cap | 147,827,904 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_4048262 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -39,119,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 141,936,215 |
| Number Of Analyst Opinions | 4 |
| Open | 1.33 |
| Operating Cashflow | -28,168,000 |
| Operating Margins | -0.64087 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 301 944 1700 |
| Post Market Change | 0.00999999 |
| Post Market Change Percent | 0.724637 |
| Post Market Price | 1.39 |
| Post Market Time | 1,783,983,063 |
| Previous Close | 1.33 |
| Price Eps Current Year | -5.018729 |
| Price Hint | 4 |
| Price To Book | 0.8806637 |
| Price To Sales Trailing12 Months | 4.578558 |
| Profit Margins | -1.2116001 |
| Quick Ratio | 10.879 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.33333 |
| Region | US |
| Regular Market Change | 0.05 |
| Regular Market Change Percent | 3.75939 |
| Regular Market Day High | 1.48 |
| Regular Market Day Low | 1.325 |
| Regular Market Day Range | 1.325 - 1.48 |
| Regular Market Open | 1.33 |
| Regular Market Previous Close | 1.33 |
| Regular Market Price | 1.38 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 2,113,589 |
| Return On Assets | -0.11316 |
| Return On Equity | -0.21301001 |
| Revenue Growth | -0.071 |
| Revenue Per Share | 0.303 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 107,121,672 |
| Shares Percent Shares Out | 0.014099999 |
| Shares Short | 1,515,592 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 4,469,961 |
| Short Name | MaxCyte, Inc. |
| Short Percent Of Float | 0.0143 |
| Short Ratio | 1.0 |
| Source Interval | 15 |
| State | MD |
| Symbol | MXCT |
| Target High Price | 5.0 |
| Target Low Price | 2.43 |
| Target Mean Price | 4.1075 |
| Target Median Price | 4.5 |
| Total Cash | 106,854,000 |
| Total Cash Per Share | 0.998 |
| Total Debt | 17,487,000 |
| Total Revenue | 32,287,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.36 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.196835 |
| Two Hundred Day Average Change | 0.18316495 |
| Two Hundred Day Average Change Percent | 0.15304111 |
| Type Disp | Equity |
| Volume | 2,113,589 |
| Website | https://www.maxcyte.com |
| Zip | 20,850 |